SCM
UTHR icon

Soleus Capital Management’s United Therapeutics UTHR Stock Holding History

Soleus Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122M Buy
225,587
+38,400
+21% +$21.6M 4.21% 6
2026
Q1 		$111M Buy
187,187
+127,187
+212% +$63.3M 4.5% 6
2025
Q4 		$29.2M Sell
60,000
-90,000
-60% -$41.9M 1.08% 24
2025
Q3 		$62.9M Sell
150,000
-59,794
-29% -$20.1M 3.17% 7
2025
Q2 		$60.3M Buy
209,794
+54,400
+35% +$16.3M 3.99% 5
2025
Q1 		$47.9M Buy
155,394
+46,000
+42% +$15.8M 3.45% 8
2024
Q4 		$38.6M Buy
109,394
+7,500
+7% +$2.76M 2.43% 13
2024
Q3 		$36.5M Sell
101,894
-39,605
-28% -$13.4M 2.83% 9
2024
Q2 		$45.1M Sell
141,499
-118,250
-46% -$31.3M 3.98% 3
2024
Q1 		$59.7M Buy
259,749
+10,300
+4% +$2.32M 4.43% 2
2023
Q4 		$54.9M Sell
249,449
-37,716
-13% -$8.69M 6.09% 2
2023
Q3 		$64.9M Buy
287,165
+44,430
+18% +$10.2M 5.98% 2
2023
Q2 		$53.6M Buy
242,735
+106,500
+78% +$23.6M 5.96% 1
2023
Q1 		$30.5M Buy
136,235
+7,967
+6% +$1.96M 3.16% 7
2022
Q4 		$35.7M Sell
128,268
-106,591
-45% -$26.9M 5.12% 3
2022
Q3 		$49.2M Sell
234,859
-60,682
-21% -$13.6M 6.68% 1
2022
Q2 		$69.6M Sell
295,541
-10,309
-3% -$2.1M 10.86% 1
2022
Q1 		$54.9M Buy
305,850
+141,550
+86% +$27M 7.08% 2
2021
Q4 		$35.5M Buy
164,300
+62,500
+61% +$12.3M 3.55% 6
2021
Q3 		$18.8M Buy
+101,800
New +$20.1M 2.93% 11

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Soleus Capital Management's UTHR Position: Q2 2026 in Review

Soleus Capital Management increased its United Therapeutics (UTHR) stake by 21% in Q2 2026, buying an estimated $21.6M and bringing the position to 225,587 shares worth $122M. The position accounts for 4.21% of the portfolio, ranked #6.

Soleus Capital Management first reported a position in UTHR in Q3 2021 and has held it in 20 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Soleus Capital Management held 225,587 shares of United Therapeutics worth $122M as of Q2 2026.
  • Soleus Capital Management bought 38,400 United Therapeutics shares in Q2 2026, an estimated $21.6M.
  • United Therapeutics made up 4.21% of Soleus Capital Management's portfolio in Q2 2026, its #6 holding.
  • Soleus Capital Management first reported a position in United Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.